DOCSLIB.ORG

Scott-Macon Healthcare Review: October 2017

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Scott-Macon Healthcare Review: October 2017 SCOTT-MACON HEALTHCARE REVIEW: OCTOBER 2017 October 2017 Healthcare Review 2 Healthcare Overview, Mean Revenue Multiples 4 Healthcare Overview, Mean EBITDA Multiples 5 Analysis of Selected Healthcare, Medical and 6 Pharmaceutical Merger and Acquisition Transactions October 1—October 31, 2017 Analysis of Selected 12 Publicly-Traded Healthcare, Medical and Pharmaceutical Companies Scott-Macon Professionals’ 23 Representative Closed Transactions Scott-Macon Contact Information 24 CONTENTS 2 OCTOBER 2017 HEALTHCARE REVIEW Dear Clients and Friends, Scott-Macon is pleased to present our PBM giant Express Scripts announced its Healthcare Review covering October 2017. $3.6 billion deal for specialty care provider If you haven’t done so already, please eviCore, formerly known as CareCore. In email me at [email protected] addition, Allscripts closed on HIT company to automatically continue receiving our PF2 for $185 million; and Murata of Japan publications in the future as we are transi- closed on Vios Medical in the wireless tioning to digital publishing with email dis- monitoring space for $101 million. In Out- tribution. sourcing Services, publicly-traded Fortive closed on Landauer for $740 million, or Pages four and five represent a visual 17x EBITDA; and Fidelity National Finan- snapshot of the average multiples for all of cial Ventures closed on T-System for $200 the healthcare, medical and pharmaceutical million. transactions that either closed or were an- nounced during October, along with the av- In the Provider arena, Ambry Genet- erage multiples for the major publicly- ics in the lab sector was acquired by Inno- traded healthcare, medical and pharmaceu- vation and Konica of Japan for $1 billion. tical companies. In the Non-Acute space, Concentra in the workers’ comp sector announced its take- In the Insurance Services space, be- over of U.S. Healthworks for $753 million, havioral-focused Magellan Healthcare and Canadian player New Vision closed on closed on its acquisition of Medicare/ IRIS in the eye care business for $93 mil- Medicaid plan provider Senior Whole lion. In Long-Term Care, BlueMountain Health for $400 million in a major diversi- closed on a cluster of facilities from Kin- fication move. In Technology Services, 3 dred for $700 million; and Sienna Senior ended October at 16.0X (up from 15.1X in Living closed on Storey Oaks of Tulsa for September 2017); Providers at 12.2X $130 million. (down from 12.6X in September 2017); and Products at 15.6X (unchangd from Turning next to Products, in Clinical 15.6X in September 2017). Technology Devices Teleflex picked up Neo Tract in services companies ended October at the urology arena for $1.1 billion; publicly- 23.7X, while Outsourcing services compa- traded Integra LifeSciences closed on nies were 16.8X. The Insurance segment DePuy Synthes’s Codman business for $1 EBITDA multiple came in at 12.4X (down billion; and Exactech went private for $625 from 12.9X in September 2017). million, or 14.6X EBITDA. In Commercial Products, Alere got sold to Abbott for $7.6 Finally, contact information for the billion, or 20.7X EBITDA; Catalent picked Scott-Macon Healthcare Investment Bank- up Cook Pharmica for $950 million; and ing Group Professionals appears on the Quidel acquired divisions of Alere for $680 back cover. We welcome your call or email million. In the Pharmaceuticals sector, to discuss your thoughts on this article. Nanjing Xinjlekou of Japan announced its deal for Dendreon Pharmaceuticals for Sincerely yours, $905 million, and publicly-traded Emer- gent BioSolutions closed on ACAM2000 for $125 million. Nathan D. Cortright Managing Director Following the mergers and acquisi- Group Head – Healthcare Investment Banking tions analysis, we present an analysis of publicly-traded Services, Providers, and Products companies by sector. Mean EBITDA multiples for Services companies 4 HEALTHCARE OVERVIEW MEAN REVENUE MULTIPLES OVERALL: Revenue Multiple 3.4x 2.9x 2.1x 1.6x 2.2x NA Services Providers Products SERVICES: Revenue Multiple 4.8x 3.2x 2.2x 1.4x 2.1x 1.9x 1.9x NA NA NA Insurance Technology Outsourcing India-Based Outsourcing Information PROVIDERS: Revenue Multiple 2.8x 1.4x 1.6x 1.3x 1.0x NA NA NA NA NA Labs Home Health & Hospice Non-Acute Long-Term Care Acute PRODUCTS: Revenue Multiple 3.2x 3.1x 2.7x 2.9x 3.4x 1.7x NA NA Clinical Devices Non-Clinical Devices Disposables Commercial 3.2x 2.3x 0.9x NA NA NA Consumer Pharmaceuticals Distribution Public Companies M&A Transactions 5 HEALTHCARE OVERVIEW MEAN EBITDA MULTIPLES OVERALL: EBITDA Multiple 17.0x 16.0x 15.6x 14.8x 12.2x NA Services Providers Products SERVICES: EBITDA Multiple 23.7x 24.2x 16.8x 17.0x 12.4x 10.3x NA NA NA NA Insurance Technology Outsourcing India-Based Outsourcing Information PROVIDERS: EBITDA Multiple 14.1x 15.1x 14.3x 11.0x 8.2x NA NA NA NA NA Labs Home Health & Hospice Non-Acute Long-Term Care Acute PRODUCTS: EBITDA Multiple 20.4x 20.7x 17.6x 17.5x 17.3x 11.9x NA NA Clinical Non-Clinical Disposables Commercial 15.0x 13.6x 10.2x NA NA NA Consumer Pharmaceuticals Distribution Public Companies M&A Transactions 6 ANALYSIS OF SELECTED HEALTHCARE, MEDICAL AND PHARMACEUTICAL SERVICES AND PRODUCTS MERGER & ACQUISITION TRANSACTIONS1 (CLOSED OR ANNOUNCED BETWEEN OCTOBER 1—OCTOBER 31, 2017) ($ Millions Except Per Share Data) Target Target Price/ Price/ Date Acquirer / Target Price Revenue EBITDA2 Revenue EBITDA2 Target Description SERVICES - INSURANCE 10/31/2017 Magellan Healthcare, Inc. / $400.0 NA NA NA NA Operates as a health maintenance organization. Senior Whole Health, LLC 10/9/2017 Paramount Care, Inc. / NA NA NA NA NA Comprises workers' health insurance plans. Health Plan of The Upper Ohio Valley Inc., Workers' Compensation Divisions MEAN (INSURANCE) NA NA MEDIAN (INSURANCE) NA NA SERVICES - TECHNOLOGY 10/2/2017 Allscripts Healthcare, LLC / $185.0 NA NA NA NA Comprises healthcare information technology PF2 EIS LLC and PF2 Enterprise Information Solutions Canada solutions. Announced ANGLEULC Biosciences Inc.; ANGLE Europe Limited / $4.9 NA NA NA NA Develops and delivers a portfolio of tools that Axela Inc. provide enhanced analysis of proteins, DNA, and RNA. 10/11/2017 Azalea Health Innovations, Inc. / NA NA NA NA NA Provides clinical enterprise software for rural and Prognosis Innovation Healthcare community hospitals and health systems. 10/24/2017 Bracket Global LLC / NA NA NA NA NA Provides mobile technologies for life science and Montentia, LLC pharmaceutical companies. 10/16/2017 Convey Health Solutions, Inc. / NA NA NA NA NA Provides health care professional and software Gorman Health Group, LLC services. 10/16/2017 Eye Care Leaders, LLC / NA NA NA NA NA Develops electronic medical record, enterprise iMedicWare Inc. practice management, and ambulatory surgery centers software for ophthalmologists. 10/24/2017 Imprivata, Inc. / NA NA NA NA NA Comprises identity and access management Caradigm USA LLC, Identity And Access Management Business solutions, including governance, risk management and compliance, and clinical and IT efficiency solutions, such as single sign-on and multi-factor authentication, to healthcare organizations. 10/3/2017 Medecision, Inc. / NA NA NA NA NA Comprises population health management AxisPoint Health, Platform Business software platform and related clientele. 10/30/2017 Medicine-On-Time / NA NA NA NA NA Provides medication management, care Clinical Support Services, Inc. management, and care coordination software and services to Medicare, Medicaid, ACO, self-insured employer, and pharmacy organizations. Announced Medsphere Systems Corporation / NA NA NA NA NA Provides software solutions and services to Stockell Healthcare Systems, Inc. manage revenue cycles for hospitals, behavioral healthcare providers, and integrated health networks. 10/13/2017 Murata Electronics North America, Inc. / $101.7 NA NA NA NA Develops wireless monitoring platform for Vios Medical, Inc. intensive healthcare applications. Announced Oz Parent, Inc. / $3,600.0 NA NA NA NA Develops and operates evidence-based cloud eviCore healthcare, LLC centric healthcare solutions for managed care organizations, self-insured entities, and risk- bearing provider organizations. 10/12/2017 Paradigm Management Services, LLC / NA NA NA NA NA Designs and develops cost containment software ForeSight Medical, LLC that provides suite of surgical management solutions in the workers' compensation marketplace. 10/3/2017 Trilliant Health, Inc. / NA NA NA NA NA Operates a big data platform that provides Expression Health Analytics LLC insights needed to make strategic decisions for healthcare organizations and providers. 10/11/2017 Unknown Buyer / NA NA NA NA NA Provides electronic data interchange solutions to Practice Insight, LLC the healthcare industry. 10/12/2017 UPMC Work Partners / NA NA NA NA NA Provides cloud based health information service. HCMS Group LLC 10/5/2017 VitalHub Corp. (TSXV:VHI) / $2.8 $1.4 NA 2.1x NA Designs and develops specialty documentation B Sharp Technologies Inc. and case management software. 10/3/2017 WebPT, Inc. / NA NA NA NA NA Develops and offers patient relationship Strive Labs, Inc. management platform for rehab therapy providers. 10/5/2017 Welltok, Inc. / $90.0 NA NA NA NA Provides SaaS-based communication solutions for Tea Leaves Health, LLC the healthcare industry. MEAN (TECHNOLOGY) 2.1x NA MEDIAN (TECHNOLOGY) 2.1x NA SERVICES - OUTSOURCING 10/20/2017 AHS Staffing, LLC / NA NA NA NA NA Offers healthcare staffing services. Advance Med, LLC 10/10/2017 Avizia, Inc. / NA NA NA NA NA Provides medical care via phone, Webcam, or Carena, Inc. house call to diagnose and treat patients’ injuries or illness. 10/24/2017 Century Ambulance Service, Inc. / NA NA NA NA NA Provides dedicated transport services to St. St. Vincent Ambulance Services Vincent HealthCare facilities. 7 Target Target Price/ Price/ Date Acquirer / Target Price Revenue EBITDA2 Revenue EBITDA2 Target Description Announced Community Care Health Network, Inc. / NA NA NA NA NA Provides case management services.
Load more

Recommended publications
  • Master Thesis Master's Programme in Industrial Management and Innovation, 120 Credits
    Master Thesis Master's Programme in Industrial Management and Innovation, 120 credits Capturing Business Model Innovation Driven by the Emergence of New Technologies in Established Firms A Case Study at Siemens Healthineers Thesis in Industrial Innovation Management, 30 credits Halmstad 2018-06-16 Emma Bäckman, Josefin Ellmarker HALMSTAD UNIVERSITY Abstract Background: It is argued that the emergence of new technologies and the digitalization can improve the healthcare, make it more efficient, personalized and available for everyone. The healthcare has already begun to become more digitized and there is no doubt that this trend will continue. Moreover, it is argued that AI will have a major impact on the MedTech and healthcare industry. Problem discussion: To stay competitive it has been concluded that firms must update and rethink their business models constantly thus, to undertake business model innovation. This applies specially to established firms that have been successful with the same business model for a long time. Despite the fact that the existing literature addresses the importance of business model innovation, very little attention has been drawn to how to actually achieve this change. Purpose: The purpose of this study is to explore how business models in established firms within the MedTech industry develops over time due to the emergence of new technologies. More specifically, we focus on how artificial intelligence is influencing and will influence the business models in the MedTech industry. Methodology: This study has been performed through a single case study at Siemens Healthineers. The primary data has been gathered through four meetings with people with expertise in the field of artificial intelligence as well as the MedTech and healthcare industry.
    [Show full text]
  • Medical Additive Manufacturing/ 3D Printing Annual Report 2018 Improving Public Health
    Medical Additive Manufacturing/ 3D Printing Annual Report 2018 Improving Public Health Each year, healthcare needs and costs grow due to an aging population, the rise in chronic diseases, and more. In fact, global healthcare spending is projected to reach nearly $9 trillion by 20201. To address this, practitioners in the healthcare industry continue to look for innovations that can provide quality care to patients at a reasonable cost. But they can’t do it alone. Today, the manufacturing industry is an important partner, with one particularly bright opportunity focused on Medical Additive Manufacturing/3D Printing (AM3DP). From anatomical models to early bioprinting applications, the use of AM3DP is providing benefits for patients and physicians/institutions including: ■ Better patient outcomes ■ Less time in the operating room ■ Reduced costs In 2017, as outlined in this Annual Report, collaboration between hospitals, device manufacturers, U.S. Food and Drug Administration (FDA), and partners such as SME, led to extraordinary strides in identifying industry trends, opportunities, challenges and solutions. These partnerships drive efficiency through best practice sharing as well as accelerate innovation for applications such as bioprinting and tissue fabrication. They also lay the groundwork for 3D printing of organs and scaling up production of tissues which are still decades away. With millions of patients already directly impacted by the technology, this momentum continues into 2018 and beyond where AM3DP will continue to positively impact public health and drive strong business results. This 2017 Annual Report covers: COVER: Justin Ryan holds a pediatric heart model 3D-printed at the ■ Industry Overview Phoenix Children’s Hospital Cardiac 3D Print Lab.
    [Show full text]
  • Healthcare & Life Sciences Group
    HEALTHCARE & LIFE SCIENCES GROUP 2 1 Healthcare and life sciences clients have long turned to S&C for help succeeding in today’s rapidly changing business environment. Large and mid-size, public and private, throughout their lifecycles, these companies rely on our multi-disciplinary, global team to address their most complex legal and business challenges and reach their strategic goals. Sector expertise: We offer unrivaled OUR CLIENTS GET… knowledge of the healthcare and life sciences industries, our clients’ businesses and the sector-specific competitive pressures bearing down on them. Sullivan & Cromwell’s Healthcare and Life Sciences Group has negotiated complex transactions and resolved high-stakes disputes for almost three decades. Today, it possesses an unparalleled grasp of these sectors and a practical understanding of the commercial realities underlying them. We position our clients to succeed through it all. The Firm represents international clients in the following healthcare sectors: Pharmaceuticals and Life Sciences Medtech Health Insurers Healthcare Services 2 Legal expertise: Clients come to us An integrated, global team: for the high-quality counsel and hands-on We’re a core group of dedicated healthcare representation we offer across multiple advisers across our 13 offices on four legal specialties, to successfully execute continents with a strong track record of their most important deals and resolve the sector’s most significant transactions critical disputes. We can execute any type and litigation matters, supported by all of transaction in any economic climate or the resources of an integrated, global firm. geographic region. Our experience in this We’re grateful to our clients for trusting sector includes: us with their future, and we’ll continue to help them position themselves for growth M&A and success in this exciting and ever- Corporate finance changing industry.
    [Show full text]
  • Conference Programme Speakers Overview
    CONFERENCE BOOK Celebrating 60 years of the benefits of innovation in medical technology to Society CONFERENCE PROGRAMME & SPEAKERS OVERVIEW 13 & 14 NOVEMBER 2019 COCIR, the European Coordination Committee of the Radiological, Electromedical and Healthcare IT Industry European Coordination Committee of the Radiological, Electromedical and Healthcare IT Industry PROGRAM WEDNESDAY 13 NOVEMBER 2019 17:30 REGISTRATION & WELCOME Drinks, Photographs 18:30 ANNIVERSARY CEREMONY OPENING BY COCIR PRESIDENT Jan KIMPEN / COCIR President and Chief Medical Officer at Royal Philips KEYNOTE SPEECHES BY EUROPEAN COMMISSION Manuel MATEO GOYET / Member of the Cabinet of Commissioner Gabriel, the Digital Economy and Society portfolio at the European Commission Andrzej RYS / Director Health Systems, Medical Products & Innovation at DG Santé, European Commission HEALTHCARE FUTUROLOGIST: “WHAT DOES THE FUTURE HOLD?” Koen KAS / Healthcare futurist, entrepreneur, professor of molecular oncology, and renowned international keynote speaker. 19:30 GALA DINNER Museum visit (optional) & Networking 2 COCIR 60 YEARS ANNIVERSARY COCIR PROGRAM PROGRAM THURSDAY 14 NOVEMBER 2019 08:30 REGISTRATION & WELCOME / Coffee 09:00 WELCOME by Nicole DENJOY / COCIR Secretary General Moderation by Maryline FIASCHI / Managing Director, Science Business 09:15 KEYNOTE SPEECH BY FINNISH PRESIDENCY Tuula HELANDER / Senior Advisor, Cabinet and Strategy Group of the Permanent Secretary, Ministry of Social Affairs and Health, Health Secretary General, Finnish Cancer Institute 09:30 SESSION
    [Show full text]
  • 2019 National Capacity Assessment Report
    National Capacity Assessment Report Pursuant to CERCLA Section 104(c)(9) December 17, 2019 U.S. Environmental Protection Agency [Page intentionally left blank.] Acronyms Used in this Report BIFs Boilers and Industrial Furnaces BR Biennial Report or Hazardous Waste Report BTU British Thermal Unit CA Cooperative Agreement CAP Capacity Assurance Plan CERCLA Comprehensive Environmental Response, Compensation, and Liability Act CFR Code of Federal Regulations EPA U.S. Environmental Protection Agency EPA ID EPA Identification Number FR Federal Register GM Form Waste Generation and Management Form LQG Large Quantity Generator RCRA Resource Conservation and Recovery Act, as amended SARA 1986 Superfund Amendments and Reauthorization Act SQG Small Quantity Generator SSC State Superfund Contract TSDFs Treatment, Storage, and Disposal Facilities VSQG Very Small Quantity Generator WR Form Waste Received from Offsite Form [Page intentionally left blank.] Table of Contents Executive Summary .................................................................................................................. i 1. Introduction ................................................................................................................. 1 Background..................................................................................................................................... 1 Purpose and Organization of Report .............................................................................................. 3 2. Data Development ......................................................................................................
    [Show full text]
  • Common Stocks — 104.5%
    Eaton Vance Tax-Advantaged Global Dividend Income Fund January 31, 2021 PORTFOLIO OF INVESTMENTS (Unaudited) Common Stocks — 104.5% Security Shares Value Aerospace & Defense — 0.8% Safran S.A.(1) 98,721 $ 12,409,977 $ 12,409,977 Banks — 6.7% Bank of New York Mellon Corp. (The) 518,654 $ 20,657,989 Citigroup, Inc. 301,884 17,506,253 HDFC Bank, Ltd.(1) 512,073 9,775,702 ING Groep NV(1) 1,676,061 14,902,461 Japan Post Bank Co., Ltd. 445,438 3,851,696 Mitsubishi UFJ Financial Group, Inc. 2,506,237 11,317,609 Mizuho Financial Group, Inc. 292,522 3,856,120 Sumitomo Mitsui Financial Group, Inc. 186,747 5,801,916 Wells Fargo & Co. 341,979 10,218,332 $ 97,888,078 Beverages — 1.0% Diageo PLC 378,117 $ 15,180,328 $ 15,180,328 Biotechnology — 1.2% CSL, Ltd. 82,845 $ 17,175,550 $ 17,175,550 Building Products — 0.9% Assa Abloy AB, Class B 509,607 $ 12,603,485 $ 12,603,485 Chemicals — 0.7% Sika AG 38,393 $ 10,447,185 $ 10,447,185 Construction & Engineering — 0.0% Abengoa S.A., Class A(1)(2) 311,491 $ 0 Abengoa S.A., Class B(1)(2) 3,220,895 0 $0 Construction Materials — 0.9% CRH PLC 332,889 $ 13,660,033 $ 13,660,033 Consumer Finance — 0.6% Capital One Financial Corp. 79,722 $ 8,311,816 $ 8,311,816 1 Security Shares Value Diversified Financial Services — 2.5% Berkshire Hathaway, Inc., Class B(1) 101,853 $ 23,209,243 ORIX Corp.
    [Show full text]
  • STOXX Changes Composition of Strategy Indices Effective on March 22Nd, 2021
    Zug, March 13th, 2021 STOXX Changes composition of Strategy Indices effective on March 22nd, 2021 Dear Sir and Madam, STOXX Ltd., the operator of Qontigo’s index business and a global provider of innovative and tradable index concepts, today announced the new composition of STOXX Strategy Indices as part of the regular quarterly review effective on March 22nd, 2021 Date Symbol Index name Internal Key ISIN Company name Changes 12.03.2021 EDEDSL STOXX Emerging Markets Diversification Select 100 USD TW01UK TW0001722007 Twn Fertilizer Addition 12.03.2021 EDEDSL STOXX Emerging Markets Diversification Select 100 USD CN0010 CNE1000002H1 CHINA CONSTRUCTION BANK CORP H Addition 12.03.2021 EDEDSL STOXX Emerging Markets Diversification Select 100 USD TW02MD TW0002301009 Liteon Tech Addition 12.03.2021 EDEDSL STOXX Emerging Markets Diversification Select 100 USD CN249E CNE000000T59 YANTAI CHANGYU PION.WINE 'B' Addition 12.03.2021 EDEDSL STOXX Emerging Markets Diversification Select 100 USD CN1I6O CNE100000HF9 CHINA MINSHENG BANKING H Addition 12.03.2021 EDEDSL STOXX Emerging Markets Diversification Select 100 USD TW025W TW0002015005 Feng Hsin Iron Addition 12.03.2021 EDEDSL STOXX Emerging Markets Diversification Select 100 USD TW505Z TW0006412000 CHICONY POWER TECHNOLOGY Addition 12.03.2021 EDEDSL STOXX Emerging Markets Diversification Select 100 USD TW0751 TW0004938006 Pegatron Addition 12.03.2021 EDEDSL STOXX Emerging Markets Diversification Select 100 USD 691316 HK0270001396 Guangdong Investment Ltd. Addition 12.03.2021 EDEDSL STOXX Emerging Markets
    [Show full text]
  • Siemens Annual Report 2018
    Annual Report 2018 siemens.com Table of contents . A B C Combined Management Report Consolidated Financial Statements Additional Information A.1 p 2 B.1 p 62 C.1 p 132 Organization of the Siemens Group Consolidated Statements Responsibility Statement and basis of presentation of Income C.2 p 133 A.2 p 3 B.2 p 63 Independent Auditor ʼs Report Financial performance system Consolidated Statements of Comprehensive Income C.3 p 139 A.3 p 6 Report of the Supervisory Board Segment information B.3 p 64 Consolidated Statements C.4 p 144 A.4 p 18 of Financial Position Corporate Governance Results of operations B.4 p 65 C.5 p 157 A.5 p 21 Consolidated Statements Notes and forward- looking Net assets position of Cash Flows statements B.5 p 66 A.6 p 22 Financial position Consolidated Statements of Changes in Equity A.7 p 26 B.6 p 68 Overall assessment of the economic position Notes to Consolidated Financial ­Statements A.8 p 28 Report on expected developments and associated material opportunities and risks A.9 p 40 Siemens AG A.10 p 43 Compensation Report A.11 p 57 Takeover-relevant information A. Combined Management Report A.1 Organization of the Siemens Group and basis of pr esentation Siemens is a technology company with core activities in the fields Non-financial matters of the Group of electrification, automation and digitalization and activities and Siemens AG in nearly all countries of the world. We are a leading supplier of Siemens has policies for environmental, employee and social power generation, power transmission and infrastructure solu- matters, for the respect of human rights, and anti-corruption and tions as well as automation, drive and software solutions for in- bribery matters, among others.
    [Show full text]
  • Siemens Healthineers · Flyer DIN Long Portrait · Template
    Dr. Roland Busch Information on the Supervisory Board candidate proposed for election under Agenda Item 6 2002 Siemens Aktiengesellschaft, Head of Memberships of comparable domestic or Infotainment Solutions Division foreign controlling bodies of commercial enterprises: 2005 Siemens VDO Automotive Asia Pacific Co. Ltd., Shanghai, China • Atos SE, Bezons, France • President and CEO • Arabia Electric Ltd. (Equipment), Jeddah, * 2007 Siemens Aktiengesellschaft, Saudi Arabia Transportation Systems Group, • ESMT European School of Management Erlangen, Germany and Technology GmbH, Berlin, Germany • Head of Mass Transit Division Dr. Roland Busch • ISCOSA Industries and Maintenance Ltd., * 2008 Siemens Aktiengesellschaft, Dammam, Saudi Arabia (deputy chairman) Deputy Chief Executive Officer, Chief Corporate Development Department, • Siemens Ltd., Riyadh, Saudi Arabia* Technology Officer and member of the Munich, Germany Managing Board of Siemens Aktien­ • Siemens W.L.L., Doha, Qatar* gesellschaft, Berlin and Munich, Germany • Head of Corporate Strategies • VA TECH T&D Co. Ltd., Riyadh, born on November 22, 1964 in Erlangen, 2011 Member of the Managing Board of Saudi Arabia* Siemens Aktiengesellschaft Germany • Chief Technology Officer since Dr. Busch is a member of the Managing December 2016 Education: Board of Siemens Aktiengesellschaft, with its • Chief Operating Officer from registered seat in Berlin and Munich. Siemens October 2018 until September 2019 • Studied physics at Friedrich Alexander since Aktiengesellschaft directly and indirectly University in Erlangen­Nuremberg, Germany, 2019 • Chairman of the Supervisory Board holds 85% of the Company’s capital stock at and at the University of Grenoble, France of Siemens Mobility GmbH since the time Notice of the Annual Shareholders’ Meeting is given. Pursuant to Section 5.4.1 (6) • Dipl.­Phys., Dr.
    [Show full text]
  • Life Sciences Newsletter Q2 2018
    KPMG Corporate Finance LLC Healthcare Life Sciences M&AQuarterly Q2 2018 © 2018 KPMG Corporate Finance LLC, a Delaware limited liability company. Member FINRA and SIPC. KPMG Corporate Finance LLC is a subsidiary of KPMG LLP, a Delaware limited liability partnership and the U.S. member firm of the KPMG network of independent member firms affiliated with KPMG International Cooperative (“KPMG International”), a Swiss entity. All rights reserved. LIFE SCIENCES M&A NEWSLETTER KPMG Corporate Finance LLC Global Life Sciences Sector Coverage(1) U.S. Life Sciences Team Jason Moran Amanda Dydynski Erik Jordan Sandy Prabhakar Managing Director & Head Senior Associate Director & Head of Director & Head of of Healthcare Life Sciences Healthcare Life Sciences Private Equity International Desk San Francisco San Francisco Los Angeles Chicago T: 415-949-8909 T: 415-963-8401 T: 213-955-8722 T: 312-665-1990 E: [email protected] E: [email protected] E: [email protected] E: [email protected] United Kingdom Germany France Canada Japan Andrew Nicholson Florian Frei Guillaume Cauchoix Neil Blair Toshiaki Ishii Ireland Sweden Spain India China Michele Connolly Christian Terslow Luis Zaragoza Sanjay Singh Andy Qiu Finland Switzerland Italy South Korea Australia Jukka Teikari Patrik Kerler Paulo Mascaretti Sung-Won Park Peter Turner Netherlands Austria Portugal Vietnam New Zealand Danny Bosker Klaus Mittermair João Leal John Ditty Gary Ivory Denmark Belgium Poland Russia Philippines Eric Bots-Bjerre Peter Lauwers Krzysztof Klamut Robert Vartevanian Michael Guarin KPMG Corporate Finance(1) KPMG Corporate Finance provides a broad range of investment banking and strategic advisory services to domestic and international clients and is a leading global middle market investment banking platform — Average 350 transactions annually for the last five years — Over 2,500 investment banking professionals worldwide — Offices in 84 countries with extensive cross-border abilities Notes: (1) Represents the global Corporate Finance practices of KPMG International’s network of independent member firms.
    [Show full text]
  • LIST of DISCLOSURES Last Name First Name Role Session Type
    LIST OF DISCLOSURES B. Research Grant (e.g. principal investigator, collaborator C. Other Research Support (e.g. receipt of drugs, supplies, D. Speakers Bureau/Honoraria (e.g. speakers bureau, E. Ownership Interest (e.g. stock options, patent or other Last Name First Name Role Session Type Session Title Day Start Time End Time A. Employment (full or part-time) or consultant and pending grants as well as grants already F. Consultant/Advisory Board (including volunteer roles) equipment or other in-kind support) symposia, and expert witness) intellectual property) received) Amit Mahajan Speaker Sessions in Co-operation Lung Surgery of the Future in co-operation with International Society for Minimally Monday 10 June 2019 16:00 17:00 Auris Robotics with other Societies Invasive Cardiothoracic Surgery (ISMICS) Arnaud Scherpereel Chair Sessions in Co-operation Mesothelioma Guidelines in co-operation with ERS/ESTRO/EACTS Tuesday 11 June 2019 15:00 16:00 BMS, Roche, Astra-Zeneca, MSD BMS, Roche, Astra-Zeneca, MSD with other Societies Arnaud Scherpereel Speaker Sessions in Co-operation Mesothelioma Guidelines in co-operation with ERS/ESTRO/EACTS Tuesday 11 June 2019 15:00 16:00 BMS, Astra-Zeneca, Roche, MSD BMS, Astra-Zeneca, Roche, MSD with other Societies Brendon Stiles Chair Educational Session ESTS Biology Club Sunday 9 June 2019 15:30 17:30 Pfizer, PPD AstraZeneca, Merck, Covidien, Lung Cancer Research Foundation Brendon Stiles Speaker Sessions in Co-operation ESTS-STS (Society of Thoracic Surgeons) Joint Session Tuesday 11 June 2019 15:00
    [Show full text]
  • Kevin M. Flannery
    Kevin M. Flannery Partner Philadelphia | Cira Centre, 2929 Arch Street, Philadelphia, PA, United States of America 19104- 2808 T +1 215 994 2814 | F +1 215 994 2222 [email protected] Services Intellectual Property > Patent Litigation > Hatch-Waxman Litigation > IP Litigation > Litigation > Trade Secrets and Unfair Competition > IP and Technology Licensing and Transactions > Life Sciences > Telecommunications, Media and Technology > Kevin M. Flannery is a nationally recognized trial lawyer who represents clients in complex patent and trade secret cases across a wide spectrum of technology areas. He has extensive experience acting as lead trial counsel in patent cases involving medical devices, pharmaceuticals, electronics, software and consumer products. Most recently, Mr. Flannery was co-counsel in a case before the U.S. Supreme Court on behalf of SCA Hygiene Products, where in a 7-1 decision, the Supreme Court overturned 100 years of precedent, concluding that laches cannot bar the award of legal damages in patent cases. Other successes include winning a US$22 million jury award in a patent case (settled favorably prior to appeal), a favorable pre-verdict settlement after a two-week jury trial in a trade secret case, and a US$4.6 million jury verdict in a patent infringement case, which was affirmed on appeal. Mr. Flannery also represents branded clients in litigation under the Hatch-Waxman Act. On behalf of Endo Pharmaceuticals, he was part of the trial team that prevailed in a five-week bench patent trial against seven manufacturers of generic drugs, winning injunctions against all seven and protecting Endo’s sales of its OPANA® ER tablets, which at its peak was the company’s second highest-selling product with US$300 million in annual sales.
    [Show full text]